Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Treasury Shares (2016 - 2019)

Gyre Therapeutics (GYRE) has disclosed Treasury Shares for 9 consecutive years, with $1.6 million as the latest value for Q3 2019.

  • On a quarterly basis, Treasury Shares rose 19.01% to $1.6 million in Q3 2019 year-over-year; TTM through Sep 2019 was $1.6 million, a 19.01% increase, with the full-year FY2017 number at $821741.0, up 482.84% from a year prior.
  • Treasury Shares was $1.6 million for Q3 2019 at Gyre Therapeutics, down from $1.6 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.6 million in Q2 2019 to a low of $44704.0 in Q1 2017.
  • A 5-year average of $920996.0 and a median of $1.0 million in 2018 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: crashed 79.89% in 2015, then soared 2195.98% in 2018.
  • Gyre Therapeutics' Treasury Shares stood at $103129.0 in 2015, then skyrocketed by 36.71% to $140990.0 in 2016, then skyrocketed by 482.84% to $821741.0 in 2017, then soared by 60.53% to $1.3 million in 2018, then grew by 19.01% to $1.6 million in 2019.
  • Per Business Quant, the three most recent readings for GYRE's Treasury Shares are $1.6 million (Q3 2019), $1.6 million (Q2 2019), and $1.6 million (Q1 2019).